Global Cord Blood (NYSE:CO) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO – Get Rating) in a report issued on Friday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

CO opened at $2.99 on Friday. Global Cord Blood has a 12 month low of $2.03 and a 12 month high of $5.50. The firm’s fifty day simple moving average is $2.99 and its 200 day simple moving average is $2.90.

Institutional Investors Weigh In On Global Cord Blood

A number of institutional investors and hedge funds have recently modified their holdings of CO. Northern Trust Corp acquired a new position in Global Cord Blood in the 2nd quarter valued at about $96,000. Benjamin F. Edwards & Company Inc. acquired a new position in Global Cord Blood in the 3rd quarter valued at $176,000. Natixis Advisors L.P. raised its holdings in Global Cord Blood by 5.6% in the 2nd quarter. Natixis Advisors L.P. now owns 199,880 shares of the medical research company’s stock valued at $592,000 after acquiring an additional 10,550 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC raised its holdings in Global Cord Blood by 99,844.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock valued at $77,957,000 after acquiring an additional 26,067,412 shares in the last quarter.

About Global Cord Blood

(Get Rating)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.